DORM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dorman Products is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 ready to deploy. The business looks fundamentally solid and the latest quarter beat expectations, but the stock is technically overbought after a sharp move and the latest financials show weaker profitability despite revenue growth. My direct view: wait for a better entry rather than buying immediately.
DORM is in an upward short-term trend, with MACD histogram positive and expanding, which confirms near-term bullish momentum. However, RSI_6 at 85.04 is deeply overbought, signaling the stock has likely run ahead of itself in the short term. Moving averages are converging, which suggests the trend is not yet fully confirmed for a fresh long-term entry. Price is near resistance at 124.18, just below R2 at 129.41, with support around 115.72. Overall: bullish momentum, but stretched and not an ideal immediate buy point.
["Q1 revenue rose 4.15% year over year to $528.8M.", "Q1 EPS of $1.57 beat expectations.", "2026 guidance calls for 7% to 9% net sales growth and EPS of $7.57 to $7.97.", "Analysts continue to rate the stock positively overall, with buy/outperform opinions from Roth Capital, Jefferies, and Barrington.", "Aurora Investment Counsel bought 25,612 shares in Q1 2026, a positive institutional signal.", "Light Duty demand remains robust, Heavy Duty is improving, and Specialty is steady."]
["Latest quarter showed weaker profitability: net income down 24.27% YoY, EPS down 23.53% YoY, and gross margin down 12.10% YoY.", "FY26 guidance was described as lower than expected by Roth Capital, causing a target cut.", "Jefferies raised the rating to Buy but still cut its target from $159 to $140, reflecting reduced expectations.", "Barrington also lowered its target, citing tariff-related noise and reduced 2026 estimates.", "RSI indicates the stock is overbought, making the current entry less attractive.", "No strong insider buying trend; insiders are neutral, and hedge funds are neutral.", "No recent congress trading data or influential figure transactions were reported beyond normal institutional buying."]
Latest quarter: Q1 2026. Revenue increased 4.15% year over year to $528.77M, which is a healthy top-line gain. However, bottom-line results weakened materially, with net income down 24.27% and EPS down 23.53% YoY, while gross margin fell to 35.96%, down 12.10% YoY. That means sales growth is still intact, but profitability was under pressure this quarter.
Analyst sentiment is still constructive overall, but the trend in price targets has turned lower. Roth Capital kept a Buy rating but cut its target to $162 from $182 after the company beat Q4 results but issued weaker FY26 guidance. Jefferies upgraded to Buy from Hold but reduced its target to $140 from $159, citing an attractive entry point after underperformance. Barrington kept Outperform but cut its target to $150 from the prior $180-$190 range due to tariff-related noise and lower 2026 estimates. Wall Street pros: long-term growth visibility, strong cash generation, improving heavy-duty demand, and robust light-duty demand. Wall Street cons: softer guidance, margin pressure, tariff noise, and reduced estimate assumptions.
